These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25820169)

  • 21. Which study when? Is gadolinium-enhanced MR imaging safer than iodine-enhanced CT?
    Weinreb JC
    Radiology; 2008 Oct; 249(1):3-8. PubMed ID: 18796663
    [No Abstract]   [Full Text] [Related]  

  • 22. Adverse reactions to intravenous iodinated contrast media: an update.
    Namasivayam S; Kalra MK; Torres WE; Small WC
    Curr Probl Diagn Radiol; 2006; 35(4):164-9. PubMed ID: 16814003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nephrogenic systemic fibrosis: a report of 29 cases.
    Shabana WM; Cohan RH; Ellis JH; Hussain HK; Francis IR; Su LD; Mukherji SK; Swartz RD
    AJR Am J Roentgenol; 2008 Mar; 190(3):736-41. PubMed ID: 18287446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventing Allergic Reactions to Gadolinium-Based Contrast Agents.
    Heshmatzadeh Behzadi A; Prince MR
    Top Magn Reson Imaging; 2016 Dec; 25(6):275-279. PubMed ID: 27748715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MR contrast agents: physical and pharmacologic basics.
    Lin SP; Brown JJ
    J Magn Reson Imaging; 2007 May; 25(5):884-99. PubMed ID: 17457803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and histological findings in nephrogenic systemic fibrosis.
    Cowper SE; Rabach M; Girardi M
    Eur J Radiol; 2008 May; 66(2):191-9. PubMed ID: 18325705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Renal toxicity of contrast agents in oncologic patients].
    Amet S; Deray G
    Bull Cancer; 2012 Mar; 99(3):295-307. PubMed ID: 22082610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI gadolinium-based contrast agents. Radiologists beware!
    Goullé JP; Cattanéo A; Saussereau E; Mahieu L; Guerbet M; Lacroix C
    Ann Pharm Fr; 2009 Sep; 67(5):335-9. PubMed ID: 19695369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immediate adverse reactions to intravenous iodinated contrast media in computed tomography.
    Juchem BC; Dall'Agnol CM
    Rev Lat Am Enfermagem; 2007; 15(1):78-83. PubMed ID: 17375236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gadolinium and nephrogenic systemic fibrosis: have we overreacted?
    Penfield JG; Reilly RF
    Semin Dial; 2011; 24(5):480-6. PubMed ID: 21913988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrast media and cutaneous reactions. Part 1. Immediate hypersensitivity reactions to contrast media and gadolinium deposition.
    Tasker F; Fleming H; McNeill G; Creamer D; Walsh S
    Clin Exp Dermatol; 2019 Dec; 44(8):839-843. PubMed ID: 31112335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse reactions to iodinated contrast media.
    Morcos SK; Thomsen HS
    Eur Radiol; 2001; 11(7):1267-75. PubMed ID: 11471623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse reactions to intravenous iodinated contrast media: a primer for radiologists.
    Namasivayam S; Kalra MK; Torres WE; Small WC
    Emerg Radiol; 2006 Jul; 12(5):210-5. PubMed ID: 16688432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A timely reminder about an evolving clinical entity: nephrogenic systemic fibrosis and gadolinium use in CKD.
    Jamboti J
    Nephrology (Carlton); 2007 Jun; 12(3):316. PubMed ID: 17498132
    [No Abstract]   [Full Text] [Related]  

  • 36. [Suggestions for prevention of adverse reactions after intravasal administration of iodinated contrast media].
    Kuefner MA; Heinrich M; Bautz W; Uder M
    Rontgenpraxis; 2008; 56(6):199-206. PubMed ID: 19294866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MRI contrast media are used to improve visualization of abnormal structures or lesions in various parts of the body. Introduction.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):153-9. PubMed ID: 18343071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
    Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
    Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
    Abu-Alfa AK
    Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacovigilance: what to do if you see an adverse reaction and the consequences.
    Stenver DI
    Eur J Radiol; 2008 May; 66(2):184-6. PubMed ID: 18372136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.